Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 659 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Antiretroviral Treatment Clear all
Completed Phase 1 Interventional

A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) Retinitis

NCT00002321
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects

NCT00654147
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir & Lopinavir/ritonavir, Raltegravir and emtricitabine/tenofovir
Drug
Lead sponsor
Margaret A. Fischl, M.D.
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2015 · Synced Sep 26, 2026, 10:46 PM EDT
Not listed Phase 1 Interventional

Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy

NCT00002449
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
Chiron Corporation
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
23
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 10:46 PM EDT
Completed No phase listed Observational

Typology of Adherence in Adolescents: Phase II

NCT00106678
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Phase 2 Interventional

A Study of Viracept in HIV-Positive Women

NCT00002171
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
13 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional Results available

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

NCT00090779
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Torrance, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 26, 2026, 10:46 PM EDT
Completed No phase listed Observational

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

NCT00238459
View directory record Official record
Conditions
HIV Infections
Interventions
Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

NCT01227824
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2018 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

NCT02175680
View directory record Official record
Conditions
HIV, Human Immunodeficiency Virus
Interventions
PRO 140, Historical data
Drug · Other
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Not applicable Interventional

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

NCT00000923
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study

NCT03639311
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA, RPV LA, RPV, DTG
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients

NCT01270802
View directory record Official record
Conditions
HIV
Interventions
Tenofovir/emtricitabine, Tenofovir/emtricitabine/efavirenz, Raltegravir
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 26, 2026, 10:46 PM EDT
Recruiting Phase 3 Interventional

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

NCT07682961
View directory record Official record
Conditions
HIV Infections
Interventions
Lenacapavir, Lenacapavir Tablet, Teropavimab, Zinlirvimab, Cabotegravir, Rilpivirine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
16
States / cities
San Francisco, California • DeLand, Florida • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 26, 2026, 10:46 PM EDT
Not listed Phase 2 Interventional

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

NCT00299897
View directory record Official record
Conditions
HIV Infections, Human Immunodeficiency Virus
Interventions
SP01A
Drug
Lead sponsor
Samaritan Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2006 · Synced Sep 26, 2026, 10:46 PM EDT
Completed No phase listed Observational

The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women

NCT00006444
View directory record Official record
Conditions
HIV Infections, Papilloma
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
49
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Adefovir (Preveon) Plus Other Anti-HIV Drugs to HIV-Infected Patients Who Have Not Responded to Other Anti-HIV Drug Combinations

NCT00002398
View directory record Official record
Conditions
HIV Infections
Interventions
Levocarnitine, Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Foster City, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 26, 2026, 10:46 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

NCT00823979
View directory record Official record
Conditions
HIV-1
Interventions
UK-453,061 Dose 1, UK-453,061 Dose 2, Etravirine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
21
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2018 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Not applicable Interventional

Study of Cell Phone SMS to Improve Adherence to ART in HIV Positive Young Women

NCT02301507
View directory record Official record
Conditions
HIV Infection
Interventions
cell phone SMS text messaging
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Phase 1 Interventional

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

NCT00000865
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 13 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • New Orleans, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 26, 2026, 10:46 PM EDT
Recruiting Phase 1 Interventional

STARLITE for Unresectable High-Grade Gliomas

NCT06428045
View directory record Official record
Conditions
High Grade Glioma
Interventions
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
Procedure · Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users

NCT01317277
View directory record Official record
Conditions
HIV, AIDS
Interventions
individualized Texting for Adherence Building (iTAB), Psychoeducation
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 26, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00001119
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 26, 2026, 10:46 PM EDT
Completed No phase listed Observational

Preparing for Pharmacy-based Delivery of Long-acting Injectable Antiretroviral Therapy (LAI-ART)

NCT05152953
View directory record Official record
Conditions
Hiv
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
63 participants
Timeline
2022 – 2023
U.S. locations
4
States / cities
Auburn, Alabama • San Francisco, California • Fort Lauderdale, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 26, 2026, 10:46 PM EDT
Terminated Phase 1 Interventional Results available

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

NCT05458102
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
Vesatolimod, Cobicistat, Voriconazole, Rifabutin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Long Beach, California • Miami, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 26, 2026, 10:46 PM EDT